Evaluation of Mangosteen juice blend on biomarkers of inflammation in obese subjects: a pilot, dose finding study.
BACKGROUND
The ability to reduce inflammation in overweight and obese individuals may be valuable in preventing the progression to metabolic syndrome with associated risks for heart disease and diabetes. The purpose of this study was to evaluate the effect of multiple dosages of a proprietary Mangosteen Juice blend on indicators of inflammation and antioxidant levels in obese patients with elevated C-reactive protein (CRP) levels.


METHODS
The study was an 8 week randomized, double-blind, placebo-controlled study with a pre-study 2 week washout period. The study included four groups including placebo and three difference doses of the test product, XanGo Juice: 3, 6 or 9 oz twice daily. The primary outcome measure of this study was high-sensitivity (HS)-CRP. Secondary outcome measures included other biochemical indicators of inflammation, anthropomorphic measures and a safety evaluation.


RESULTS
One hundred twenty two (122) persons were screened for the study, 44 were randomized and 40 completed the study. HS-CRP measurements dropped after 8 weeks treatment compared to baseline in all 3 dose groups and increased in the placebo group. The changes from baseline were not significant but the comparison of change from baseline was significant for the 18 oz group when compared to placebo (p = 0.02). Other markers of inflammation (inflammatory cytokines) and a marker for lipid peroxidation (F2 isoprostane) did not show any significant differences when compared with placebo. There was a trend towards a decrease in BMI in the juice groups. There were no side effects reported in any of the groups and none of the laboratory or EKG safety assessments indicated clinically significant changes for any subject.


CONCLUSIONS
In this pilot, dose-finding study, a proprietary mangosteen juice blend (XanGo Juice) reduced CRP levels (increased change from baseline) compared to placebo for those taking the highest dose of 18 oz per day. Further studies with a larger population are required to confirm and further define the benefits of this juice. The juice was administered safely.


BACKGROUND
ISRCTN9300027.
Udani
Jay K
JK
Medicus Research LLC, Northridge, CA 91325, USA. jay.udani@medicusresearch.com
Singh
Betsy B
BB
Barrett
Marilyn L
ML
Singh
Vijay J
VJ
D000273:Adipose Tissue; D000328:Adult; D000368:Aged; D001628:Beverages / Q000009:adverse effects; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis; D004311:Double-Blind Method; D028441:F2-Isoprostanes / Q000097:blood; D005260:Female; D005638:Fruit / Q000009:adverse effects; D029762:Garcinia mangostana / Q000009:adverse effects; D006801:Humans; D007249:Inflammation / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D008517:Phytotherapy / Q000009:adverse effects; D010865:Pilot Projects; D013997:Time Factors
D028441:F2-Isoprostanes; D018836:Inflammation Mediators; D002097:C-Reactive Protein